As premature infants often have under-developed lungs, oxygen is administered following birth. One devastating side effect, however, is the development of retinopathy of prematurity (ROP), whereupon oxygen administration to the infant suppresses the expression of essential growth factors that promote the development of retinal blood vessels, resulting in blindness. In the July 1 issue of the Journal of Clinical Investigation, a study by researchers at Harvard Medical School and Childrens Hospital, Boston investigating the development of the retinal vasculature in mice demonstrates that specific activation of the receptor VEGFR-1 by the growth factor PlGF-1 protects against oxygen-induced vessel loss.
ROP occurs in two distinct stages. First, exposure to high levels of oxygen causes obliteration of immature retinal vessels. The second phase, initiated upon return to breathing normal air, results in an adverse overcompensation of new vessel growth. The new vessels are excessive in number and often leaky. The inner membrane of the retina can be breached, whereby vessels grow into the vitreous of the eye causing retinal detachment and blindness.
The process of vasculature development is mediated in part by the growth factor VEGF. It had been shown previously that vessels can be rescued by administration of VEGF, suggesting that VEGF might be used in the treatment of ROP. However, this theory presents a double-edged sword as VEGF also stimulates abnormal vessel growth that can ultimately result in leaky vessels.
A whole-body approach to understanding chemosensory cells
13.12.2017 | Tokyo Institute of Technology
Research reveals how diabetes in pregnancy affects baby's heart
13.12.2017 | University of California - Los Angeles Health Sciences
11.12.2017 | Event News
08.12.2017 | Event News
07.12.2017 | Event News
13.12.2017 | Health and Medicine
13.12.2017 | Physics and Astronomy
13.12.2017 | Life Sciences